Indian Journal of Science and Technology

Open Access Open Access  Restricted Access Subscription Access

Evaluation of Seizure Activity after Phospho-diesterase and Adenylate Cyclase Inhibition (SQ22536) in Animal Models of Epilepsy


Affiliations
1 Department of Pharmacology, Christian Medical College, Vellore-632002, TN, India
 

The role of adenylate cyclase (AC) inhibitor (SQ22536) was evaluated in the presence of PDE-5/6/8/10/11 and PDE-7 inhibitors such as dipyridamole and BRL-50481 in animal models of epilepsy. Seizures were induced in the animals by subjecting them to injection of chemical convulsant, pentylenetetrazole (PTZ) and maximal electroshock (MES). The study mainly comprises of the onset of seizures, mortality/recovery, percentage of prevention of seizures (anticonvulsant) and total duration of convulsive time. Present study mainly highlights the combined effects of AC inhibitor SQ22536 with dipyridamole as well as BRL50481 showed a good reduction (P<0.001) in incidence of seizures, compared to SQ22536 and BRL50481 alone treated mice against PTZ (60 mg/kg, i.p.) model. The total convulsive time was prolonged significantly (P<0.01) in SQ22536 alone treated (60.2%) and in with combination of SQ22536 with BRL50481 treated (27.4%) groups, compared to DMSO received group (100%). The study also demonstrates that SQ22536 alone, SQ22536 followed by dipyridamole and SQ22536 with BRL50481 greatly increased the anticonvulsant activity (P<0.01, P<0.05 and P<0.01) along with higher protection 83.3%, 66.7% and 50% range respectively. SQ22536 with dipyridamole effectively (P<0.001) decreased the MES (150 mA, 0.2 sec) induced convulsion, compared to SQ22536. The data shows that SQ22536 alone, SQ22536 followed by dipyridamole and SQ22536 with BRL50481 greatly increased the anti-convulsant activity (P<0.01, P<0.01 and P<0.01) along with higher protection 83.3%, 50% and 66.7% range respectively in animals pre-treated with MES. The results suggest the possible involvement of SQ22536 alone and with presence of dipyridamole and BRL50481, delays the onset of seizure activity as well as prolongs the total duration of convulsive time in both models.

Keywords

Adenylate cyclase, PDE, SQ22536, Dipyridamole, BRL50481, Seizures
User

  • Achliya GS, Wadodkar SG and Darle AK (2005) Evaluation of CNS activity of Bramhi Ghrita. Ind. J. Pharmacol. 37, 33-36.

  • Adkinson: Middleton's allergy (2008) Principles and practice, 7th ed. copyright © Mosby, an imprint of Elsevier.

  • Conti M and Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nuclic Acid Res. Mol. Biol. 63, 1-38.

  • Ferrendelli JA, Blank AC, Gross RA (1980) Relationships between seizure activity and cyclic nucleotide levels in brain. Brain Res. 200, 93-103.

  • Fisher RS & Coyle JT (1991) In summary: Neurotransmitters and epilepsy (Wiley-Liss: New york) 247.

  • Francis SH, Thomas MK and Corbin JD (1990) Cyclic GMP-binding cyclic GMP-specific phosphodiesterase from lung. In cyclic nucleotide phosphodiesterases: Structure, regulation and drug action (Beavo J & Houslay MD, eds.), John Wiley & Sons, Chichester, pp117–139.

  • Gamboa A, Abraham R, Diedrich A, Shibao C, Paranjape SY, Farley G and Biaggioni I (2005) Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke. 36, 2170–2175.

  • Gao Y and Usha Raj J (2001) SQ22536 and W-7 inhibit forskolin-induced cAMP elevation but not relaxation in newborn ovine pulmonary veins. Euro. J. Pharmacol. 418, 111-116.

  • Gardner C, Robas N, Cawkill D and Fidock M (2000) Cloning and characterization of the human and mouse PDE 7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 272, 186-192.

  • Gardner C, Robas N, Cawkill D and Fidock M (2000) Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 272, 186-192.

  • Glavas NA, Ostenson C, Schaefer JB, Vasta V and Beavo JA (2001) T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc. Natl. Acad. Sci. USA. 98, 6319-6324.

  • Gresele P, Arnout J, Deckmyn H and Vermylen J (1986) Mechanism of antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb. Haemostasis. 55, 12–18.

  • Haslam RJ, Davidson MM and Desjardins JV (1978) Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP. Biochem. J. 176, 83–95.

  • Hetman JM, Soderling SH, Glavas NA and Beavo JA (2000) Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc. Natl. Acad. Sci. USA 97, 472- 476.

  • Higashima M, Ohno K and Kushino Y (2002) Cyclic AMPmediated modulation of epileptiform after discharge generation in rat hippocampal slices. Brain Res. 949, 157-161.

  • Houslay MD (1998) Adaptation in cyclic AMP signaling processes: A central role for cyclic AMP phosphodiesterases. Seminal Cell Development Biol. 9, 161-167.

  • Houslay MD (2001) PDE 4 cAMP-specific phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 69, 249-315.

  • Houslay MD and Milligan G (1997) Tailoring cAMPSignalling responses through isoform multiplicity. Trend. Biochem. Sci. 22, 217-224.

  • Houslay MD, Sullivan M and Bolger GB (1998) The multienzyme PDE4 cyclic adenosine monophosphate specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and anti-depressant actions. Adv. Pharmacol. 44, 225-342.

  • Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S and Cho JM (2005) Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol. Life Sci. 62(11), 1198-1220.

  • Krivanek J and Mares P (1977) Cyclic adenosine 3', 5’- monophosphate in epileptogenic foci induced by penicillin. Neurosci. Lett. 6, 329-332.

  • Li L, Yee C and Beavo JA (1999) CD3 and CD28 dependent induction of PDE7 required for T cell activation. Science. 283, 848-851.

  • Liao JK (2007) Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation. 115, 1615–1621.

  • Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM and Sonnenburg WK (1998) Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3’,5’cyclic nucleotide phosphodiesterase. Gene. 216, 139–147.

  • Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K and Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3’,5’-cyclic nucleotide phosphodiesterase. Gene. 234, 109–117.

  • Lowenstein DH (2001) Seizures and epilepsy in Harrison's principles of internal medicine. Vol. 1 edited by Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL and Jameson JL (McGraw-hill medical publishing division, New York). p2354.

  • Lugnier C, Schoeffter P, Le Bec A, Strowthou E, Stoclet JC and Strasbourg FR (1986) Selective inhibition of cyclic nucleotide phosphodiesterase of human, bovine and rat aorta. Biochem. Pharmacol. 35, 1743–1751.

  • Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ and Raymond DR (2003) Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64, 533-546.

  • Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA and Wigler M (1993) Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J. Biol. Chem. 268, 12925–12932.

  • Miro X, Perez-Torres S, Palacios JM, Puigdomenech P and Mengod G (2001) Differential distribution of cAMPspecific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse. 40, 201-214.

  • Mons N, Decorte L, Jaffard R and Cooper DM (1998) Ca2+-sensitive adenylyl cyclases, key integrators of cellular signalling. Life Sci. 62, 1647–1652.

  • Murray KJ (1990) Cyclic AMP and mechanisms of vasodilation. Pharmacol. Ther. 47, 329–345.

  • Myllyla VV, Heikkinen ER, Vapatalo H and Hokkanen E (1975) Cyclic AMP concentration and enzyme activities of cerebrospinal fluid in patients with epilepsy or central nervous system damage. Eur. Neurol. 13, 123-130.

  • Porter RJ (1988) Therapy of epilepsy. Curr. Opin. Neurol. Neurosurg. 1(2), 206-211.

  • Reyes-Irisarri E, Perez-Torres S and Mengod G (2005) Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neurosci.132, 1173-85.

  • Roos H and Pleger K (1972) Kinetics of adenosine uptake by erythrocytes, and the influence of dipyridamole. Mol. Pharmacol. 8, 417–425.

  • Salahdeen HM and Yemitan OK (2006) Neuro pharmacological effects of aqueous leaf extract of Bryophyllum pinnatum in mice. Afr. J. Bio. Med. Res. 9, 101-107.

  • Scharfman HE (2007) The neurobiology of epilepsy, current neurology and neuroscience reports. 7(4), 348-354.

  • Seamon KB, Padgett W and Daly JW (1981) Forskolin: unique diterpene activator of adenylate cyclase in membranes and intact cells. Proc. of the Nat. Academy of Sci. of the USA. 78, 3363-3367.

  • Soderling SH, Bayuga SJ and Beavo JA (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl. Acad. Sci. USA, 95, 8991–8996.

  • Soldering SH and Beavo JA (2000) Regulation of cAMP and cGMP signalling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. 12, 174-179.

  • Sunahara RK, Dessauer CW and Gilman AG (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu. Rev. Pharmacol. Toxicol. 36, 461–480.

  • Torras-Llort M and Azorin F (2003) Functional characterization of the human phosphodiesterase 7A1 promoter. Biochem. J. 373, 835-843.

  • Turcato S and Clapp LH (1999) Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta. Br. J. Pharmacol. 126, 845–847.

  • Walker JE, Lewin E, Sheppard JR and Cromwell R (1973) Enzymatic regulation of adenosine 3',5'- monophosphate (cyclic AMP) in the freezing epileptogenic lesion of rat brain and in homologus contralateral cortex. J. Neurochem. 21, 79-85.

  • Wallace DA, Johnston LA, Huston E, Macmaster D, Houslay TM and Cheung YF (2005) Identification and characterization of PDE4A11 a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene. Mol. Pharmacol. 67, 1920– 1934.

  • Wang P, Wu P, Myers JG, Stamford A, Egan RW and Billah MM (2001) Characterization of human, dog and rabbit corpus cavernosum type 5 phosphodiesterases. Life Sci. 68, 1977–1987.

  • Yemitan OK and Salahdeen HM (2005) Neuroselective and muscle relaxant activities of aqueous extract of Bryophyllum pinnatum. Fitoterpia. 76,187-93.

  • Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T and Omori K (2000) Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J. Biol. Chem. 275, 31469–31479.


Abstract Views: 557

PDF Views: 125




  • Evaluation of Seizure Activity after Phospho-diesterase and Adenylate Cyclase Inhibition (SQ22536) in Animal Models of Epilepsy

Abstract Views: 557  |  PDF Views: 125

Authors

J. Nandhakumar
Department of Pharmacology, Christian Medical College, Vellore-632002, TN, India
Manoj G. Tyagi
Department of Pharmacology, Christian Medical College, Vellore-632002, TN, India

Abstract


The role of adenylate cyclase (AC) inhibitor (SQ22536) was evaluated in the presence of PDE-5/6/8/10/11 and PDE-7 inhibitors such as dipyridamole and BRL-50481 in animal models of epilepsy. Seizures were induced in the animals by subjecting them to injection of chemical convulsant, pentylenetetrazole (PTZ) and maximal electroshock (MES). The study mainly comprises of the onset of seizures, mortality/recovery, percentage of prevention of seizures (anticonvulsant) and total duration of convulsive time. Present study mainly highlights the combined effects of AC inhibitor SQ22536 with dipyridamole as well as BRL50481 showed a good reduction (P<0.001) in incidence of seizures, compared to SQ22536 and BRL50481 alone treated mice against PTZ (60 mg/kg, i.p.) model. The total convulsive time was prolonged significantly (P<0.01) in SQ22536 alone treated (60.2%) and in with combination of SQ22536 with BRL50481 treated (27.4%) groups, compared to DMSO received group (100%). The study also demonstrates that SQ22536 alone, SQ22536 followed by dipyridamole and SQ22536 with BRL50481 greatly increased the anticonvulsant activity (P<0.01, P<0.05 and P<0.01) along with higher protection 83.3%, 66.7% and 50% range respectively. SQ22536 with dipyridamole effectively (P<0.001) decreased the MES (150 mA, 0.2 sec) induced convulsion, compared to SQ22536. The data shows that SQ22536 alone, SQ22536 followed by dipyridamole and SQ22536 with BRL50481 greatly increased the anti-convulsant activity (P<0.01, P<0.01 and P<0.01) along with higher protection 83.3%, 50% and 66.7% range respectively in animals pre-treated with MES. The results suggest the possible involvement of SQ22536 alone and with presence of dipyridamole and BRL50481, delays the onset of seizure activity as well as prolongs the total duration of convulsive time in both models.

Keywords


Adenylate cyclase, PDE, SQ22536, Dipyridamole, BRL50481, Seizures

References





DOI: https://doi.org/10.17485/ijst%2F2010%2Fv3i7%2F29799